UA130812U - METHOD OF FORECASTING OSTEOARTHrosis DEVELOPMENT - Google Patents

Abstract

A method for predicting the development of osteoarthritis includes clinical examination, radiography, determination of serum MTHFR C677T gene polymorphism, GAG content, PSA, IL-6, homocysteine. With homozygous carrier 677-TT and levels of GAG> 28 μmol / l, PSA> 6 mg / l, IL-6> 10 ng / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - T. 2. - E. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, prevention of its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that the method of predicting the development of osteoarthritis includes the determination of the polymorphism of the methylenetetrahydrofolate reductase gene (MITNEVK C677T), the content of glycosaminoglycans, C-reactive protein (CRP), interleukin 6 (IL-6), homocysteine in the patient's blood serum, and in case of homozygous carrier 677 -TT, contents

GAG »28 μmol/l, SRP »6 mg/l, IL-6 »10 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, an X-ray is taken, and the MTNEV C677T gene polymorphism is determined. The GAG content is determined by the immunoenzymatic method,

SRP, IL-6, homocysteine. With homozygous carrier 677-TT, levels of GAG »28 μmol/l, SRP »6 mg/l, IL-6 »10 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient L., 56 years old, was admitted to the clinic due to pain in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content was determined by the immunoenzymatic method

GAG, SRP, IL-6, homocysteine. A homozygous carrier of 677-GTT was established. GAG levels - 39 μmol/l, SRP - 14 mg/l, IL-6-21 ng/l, homocysteine - 32 μmol/l. The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Zo

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which differs in that the MTNEV C677T gene polymorphism, the content of HAG, SRP, IL-b6, homocysteine are determined in the blood serum, with homozygous carrier 677-177 and levels of HAG »28 μmol/l, SRP »b mg/l, IL-b »10 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.